Familial hyperphosphatemic tumoral calcinosis in an unusual and usual sites and dramatic improvement with the treatment of acetazolamide, sevelamer and topical sodium thiosulfate
Author:
Emecen Sanli Merve1, Kilic Ayse1, Aktasoglu Ekin1, Inci Asli1ORCID, Okur Ilyas1, Ezgu Fatih1, Tumer Leyla1
Affiliation:
1. Department of Inborn Errors of Metabolism , Faculty of Medicine, Gazi University , Ankara , Turkey
Abstract
Abstract
Objectives
Familial hyperphosphatemic tumoral calcinosis is a rare disorder characterized by hyperphosphatemia with recurrent ectopic periarticular calcifications, in addition to other visceral and vascular manifestations, without any inflammatory or neoplastic disorder. The available treatment strategies are limited. Here we report an eight year old female patient with recurrent lesions under the chin, and bilateral hips which are painful and improving of the size of the lesions and hyperphosphatemia.
Case presentation
The patient was started to the treatment with peroral acetazolamide however the lesion did not regress but a new lesion appeared then we added sevelamer and topical sodium thiosulfate treatment for three months. After the three months of the combination treatment the lesions, there were no pain, no hyperphospahtemia regression/disappearance of the lesions.
Conclusions
This combination treatment or topical sodium thiosulfate use only may be a novel treatment strategy for the patients prospective controlled trials are needed.
Publisher
Walter de Gruyter GmbH
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology, and Child Health
Reference17 articles.
1. Giard, A. Sur la calcification hibernale. CR Soc Biol 1898;10:1013–5. 2. Olsen, KM, Chew, FS. Tumoral calcinosis: pearls, polemics, and alternative possibilities 1. Radiographics 2006;26:871–85. https://doi.org/10.1148/rg.263055099. 3. Jost, J, Bahans, C, Courbebaisse, M, Tran, T-A, Linglart, A, Benistan, K, et al.. Topical sodium thiosulfate: a treatment for calcifications in hyperphosphatemic familial tumoral calcinosis? J Clin Endocrinol Metab 2016;101:2810–5. https://doi.org/10.1210/jc.2016-1087. 4. Riminucci, M, Collins, MT, Fedarko, NS, Cherman, N, Corsi, A, White, KE, et al.. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003;112:683–92. https://doi.org/10.1172/JCI18399. 5. Yamamoto, H, Ramos-Molina, B, Lick, AN, Prideaux, M, Albornoz, V, Bonewald, L, et al.. Posttranslational processing of FGF23 in osteocytes during the osteoblast to osteocyte transition. Bone 2016;84:120–30. https://doi.org/10.1016/j.bone.2015.12.055.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|